Browsing by author "Brand, Douglas"
Now showing items 1-16 of 16
-
Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy.
Pathmanathan, AU; McNair, HA; Schmidt, MA; Brand, DH; Delacroix, L; et al. (BRITISH INST RADIOLOGY, 2019-03-01)OBJECTIVE:: With increasing incorporation of MRI in radiotherapy, we investigate two MRI sequences for prostate delineation in radiographer-led image guidance. METHODS:: Five therapeutic radiographers contoured the prostate ... -
Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation.
Wilkins, A; Naismith, O; Brand, D; Fernandez, K; Hall, E; et al. (ELSEVIER SCIENCE INC, 2020-04-01)PURPOSE: The CHHiP trial randomized 3216 men with localized prostate cancer (1:1:1) to 3 radiation therapy fractionation schedules: 74 Gy in 37 fractions over 7.4 weeks; 60 Gy in 20 fractions over 4 weeks; and 57 Gy in 19 ... -
Dosimetric comparison of automatically propagated prostate contours with manually drawn contours in MRI-guided radiotherapy: A step towards a contouring free workflow?
Sritharan, K; Dunlop, A; Mohajer, J; Adair-Smith, G; Barnes, H; et al. (ELSEVIER IRELAND LTD, 2022-11-01)BACKGROUND: The prostate demonstrates inter- and intra- fractional changes and thus adaptive radiotherapy would be required to ensure optimal coverage. Daily adaptive radiotherapy for MRI-guided radiotherapy can be both ... -
Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
Brand, DH; Brüningk, SC; Wilkins, A; Fernandez, K; Naismith, O; et al. (ELSEVIER SCIENCE INC, 2021-06-01)PURPOSE: Changes in fraction size of external beam radiation therapy exert nonlinear effects on subsequent toxicity. Commonly described by the linear-quadratic model, fraction size sensitivity of normal tissues is expressed ... -
Fractionation Choice for Elective Lymph Node Radiation Therapy in Prostate Cancer: Slightly More to CHIRP About.
Brand, DH; Tree, AC (Elsevier BV, 2022-07-14) -
Fractionation Choice for Elective Lymph Node Radiation Therapy in Prostate Cancer: Slightly More to CHIRP About.
Brand, DH; Tree, AC (Elsevier BV, 2022-07-14) -
Gastrointestinal Toxicity Prediction Not Influenced by Rectal Contour or Dose-Volume Histogram Definition.
Brand, DH; Brüningk, SC; Wilkins, A; Naismith, O; Gao, A; et al. (ELSEVIER SCIENCE INC, 2023-12-01)PURPOSE: Rectal dose delivered during prostate radiation therapy is associated with gastrointestinal toxicity. Treatment plans are commonly optimized using rectal dose-volume constraints, often whole-rectum relative-volumes ... -
How Low Can You Go? The Radiobiology of Hypofractionation.
Brand, DH; Kirby, AM; Yarnold, JR; Somaiah, N (ELSEVIER SCIENCE LONDON, 2022-05-01)Hypofractionated radical radiotherapy is now an accepted standard of care for tumour sites such as prostate and breast cancer. Much research effort is being directed towards more profoundly hypofractionated (ultrahypofractionated) ... -
Improving fiducial and prostate capsule visualization for radiotherapy planning using MRI.
Pathmanathan, AU; Schmidt, MA; Brand, DH; Kousi, E; van As, NJ; et al. (WILEY, 2019-03-01)BACKGROUND AND PURPOSE: Intraprostatic fiducial markers (FM) improve the accuracy of radiotherapy (RT) delivery. Here we assess geometric integrity and contouring consistency using a T2*-weighted (T2*W) sequence alone, ... -
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand, DH; Tree, AC; Ostler, P; van der Voet, H; Loblaw, A; et al. (ELSEVIER SCIENCE INC, 2019-09-17)BACKGROUND: Localised prostate cancer is commonly treated with external-beam radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional fractionation. Ultra-hypofractionated stereotactic ... -
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree, AC; Ostler, P; van der Voet, H; Chu, W; Loblaw, A; et al. (ELSEVIER SCIENCE INC, 2022-10-01)BACKGROUND: Localised prostate cancer is commonly treated with external beam radiotherapy and moderate hypofractionation is non-inferior to longer schedules. Stereotactic body radiotherapy (SBRT) allows shorter treatment ... -
Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation.
Brand, D; Parker, C (ELSEVIER, 2018-04-01)In men with prostate-specific antigen failure after radical radiotherapy, androgen deprivation therapy should be delayed until the site of recurrence is known to allow consideration of curative treatment options, to delay ... -
Patterns of recurrence after prostate bed radiotherapy.
Brand, DH; Parker, JI; Dearnaley, DP; Eeles, R; Huddart, R; et al. (ELSEVIER IRELAND LTD, 2019-12-01)BACKGROUND AND PURPOSE: Prostate bed radiotherapy is a standard treatment after radical prostatectomy. Recent evidence suggests that, for patients with a PSA > 0.34 ng/ml, the radiotherapy treatment volume should include ... -
Predictors of toxicity in prostate hypofractionation clinical trials
Van As, N; Brand, D (Institute of Cancer Research (University Of London), 2021-06-30) -
The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B Study.
Ratnakumaran, R; Hinder, V; Brand, D; Staffurth, J; Hall, E; et al. (MDPI, 2023-02-17)Several studies have demonstrated the association between acute and late radiotherapy toxicity in prostate cancer using older radiotherapy techniques. However, whether this association is present with newer techniques such ... -
The Fraction Size Sensitivity of Late Genitourinary Toxicity: Analysis of Alpha/Beta (α/β) Ratios in the CHHiP Trial.
Brand, DH; Brüningk, SC; Wilkins, A; Naismith, O; Gao, A; et al. (ELSEVIER SCIENCE INC, 2023-02-01)PURPOSE: Moderately hypofractionated external beam intensity modulated radiation therapy (RT) for prostate cancer is now standard-of-care. Normal tissue toxicity responses to fraction size alteration are nonlinear: the ...